Such results are expected in view of the marked participation of CD4+ T and CD8+ T cells in the anti-tumor response and their role as important sources of wild-type IL-2 (wtIL-2) cytokine production upon cell activation [31, 43]. The gene discussed is CD8A; the disease is neoplasm.